Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EIK1003 + paclitaxel
- Development stage
- Unknown
- Lead developer
- IMPACT Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
EIK1003 + paclitaxel is an investigational combination regimen consisting of EIK1003 (formerly IMP1734), an oral, highly selective, non-brain-penetrant PARP1 inhibitor, and paclitaxel, an established microtubule-stabilizing cytotoxic chemotherapy. Developed by Eikon Therapeutics in collaboration with Impact Therapeutics, EIK1003 is designed to selectively target PARP1 while sparing PARP2, thereby minimizing the hematologic toxicities (such as myelosuppression) typically associated with first-generation, non-selective PARP inhibitors. This improved safety profile is intended to allow near full-dose combinations with chemotherapy. The combination is currently being evaluated in a Phase 1/2 clinical trial (NCT06253130) for the treatment of advanced solid tumors, specifically focusing on platinum-resistant recurrent ovarian cancer and HER2-negative breast cancer.
- Other names
- EIK1003 + PTXIMP1734 + PTXIMP1734 + paclitaxelPTX + EIK1003PTX + IMP1734paclitaxel + EIK1003paclitaxel + IMP1734
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on EIK1003 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EIK1003 + paclitaxel.